GeNeuro SA announces the liquidation of its French subsidiary

GeNeuro SA, a Geneva-based biopharmaceutical company, announced that its French subsidiary, GeNeuro Innovation SAS, is in receivership. This decision was issued by the Lyon Economic Activities Court on July 15, 2025. SELARL MJ-Synergie has been appointed as receiver.

This liquidation comes as GeNeuro undergoes a restructuring process. In May, the company obtained a debt restructuring order in Switzerland, valid until September 28, 2025, which remains in effect despite the situation of its subsidiary. GeNeuro SA continues its efforts to develop treatments for neurodegenerative and autoimmune diseases.